| pubmed-article:21381013 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21381013 | lifeskim:mentions | umls-concept:C0150369 | lld:lifeskim |
| pubmed-article:21381013 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:21381013 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:21381013 | lifeskim:mentions | umls-concept:C0935989 | lld:lifeskim |
| pubmed-article:21381013 | lifeskim:mentions | umls-concept:C2709058 | lld:lifeskim |
| pubmed-article:21381013 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:21381013 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21381013 | pubmed:dateCreated | 2011-3-7 | lld:pubmed |
| pubmed-article:21381013 | pubmed:abstractText | The current study was conducted to compare simultaneously obtained bone marrow (BM) cytogenetics (CTG), peripheral blood (PB) and BM fluorescence in situ hybridization (FISH), and quantitative real-time polymerase chain reaction (Q-PCR) for BCR-ABL1 in monitoring response to treatment with tyrosine kinase inhibitors and homoharringtonine (HHT) in patients with chronic myeloid leukemia (CML). | lld:pubmed |
| pubmed-article:21381013 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21381013 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21381013 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21381013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21381013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21381013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21381013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21381013 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21381013 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:21381013 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:RoaV HVH | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:MannKaren PKP | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:Bernal-Mizrac... | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:ArellanoMarth... | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:LangstonAmeli... | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:TighiouartMou... | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:WintonElliott... | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:KhouryHanna... | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:McLemoreMorga... | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:SaxeDebraD | lld:pubmed |
| pubmed-article:21381013 | pubmed:author | pubmed-author:HeffnerLeonar... | lld:pubmed |
| pubmed-article:21381013 | pubmed:copyrightInfo | Copyright © 2010 American Cancer Society. | lld:pubmed |
| pubmed-article:21381013 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:21381013 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:21381013 | pubmed:volume | 117 | lld:pubmed |
| pubmed-article:21381013 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21381013 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21381013 | pubmed:pagination | 1245-52 | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:meshHeading | pubmed-meshheading:21381013... | lld:pubmed |
| pubmed-article:21381013 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21381013 | pubmed:articleTitle | Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. | lld:pubmed |
| pubmed-article:21381013 | pubmed:affiliation | Department of Hematology and Medial Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA. | lld:pubmed |
| pubmed-article:21381013 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21381013 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
